Baird Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Shares continue trading uninterrupted, but failure to regain compliance may lead to delisting unless an additional grace period is available.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Baird Medical (NASDAQ: BDMD) received a Nasdaq notification dated November 2, 2026, that it does not meet the minimum bid price requirement. The notice does not delist its shares, which continue trading uninterrupted on the Nasdaq Capital Market.
The company has 180 calendar days, until May 3, 2027, to regain compliance. Its ordinary shares must close at US$1.00 or above for at least ten consecutive business days. If compliance is not restored by the deadline, Baird Medical may qualify for another 180-calendar-day period or face delisting. The company is exploring options to regain compliance.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- None.
Negative
- Major pointNasdaq minimum bid price deficiency puts Baird Medical out of compliance with continued listing requirements.
- Minor point. Forward-looking: it has not happened yet and may not happen.May 3, 2027 deadline requires closing bids of US$1.00 or above for at least ten consecutive business days.
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential delisting follows failure to regain compliance; an additional 180-calendar-day grace period is conditional.
News Explained
If it does not cure the deficiency by
Details
Market Reaction – BDMD
On Nov 4, the day this news came out, the latest delayed price for BDMD is 9.44% below the previous close. Our momentum scanner has recorded 16 alerts for this stock so far that day. The latest delayed price is $0.10. Relative volume is exceptionally heavy at 86.3x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Minimum bid price
- US$1.00 per share
- Nasdaq continued-listing requirement
- Deficiency period
- 30 consecutive business days
- Period constituting a minimum bid price deficiency
- Compliance period
- 180 calendar days
- Through May 3, 2027
- Required bid-price duration
- 10 consecutive business days
- Closing bid price must be at least US$1.00
- Potential additional grace period
- 180 calendar days
- May be available if the company meets additional listing conditions
Key Terms
microwave ablation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings Limited (NASDAQ: BDMD) (“Baird Medical” or the “Company”), a healthcare innovator dedicated to microwave ablation (MWA) technology, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated November 2, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This notification does not result in the delisting of the Company’s shares, and Baird Medical’s shares will continue to trade, uninterrupted, on the Nasdaq Capital Market under the ticker “BDMD.”
Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until Monday, May 3, 2027, to regain compliance with the minimum bid price rule. To regain compliance, the Company’s ordinary shares must have a closing bid price of US
This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The Company is currently looking into various options available with respect to regaining such compliance. The notification letter has no effect at this time on the listing of the Company’s ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker “BDMD.”
About Baird Medical
Baird Medical is a global, pioneering medical device company specializing in minimally invasive ablation technologies for a range of solid tumors. The Company’s lead product, a microwave ablation (MWA) system, is FDA-cleared for soft tissue ablation and is being launched in the U.S. primarily for the treatment of benign thyroid nodules. In addition, the Company is expanding its minimally invasive technology portfolio, including IRE-based products and an AI-powered robotic ablation system.
Baird Medical's MWA solutions have been adopted by a growing number of leading U.S. institutions and private practice groups, including the Mayo Clinic, Columbia University Medical Center, and The George Washington University Hospital. The company is rapidly expanding its global commercial footprint, with sales now reaching markets across multiple continents.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.
The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein, or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Lee Roth
Burns McClellan for Baird Medical
Lroth@burnsmc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Baird Medical's Nasdaq bid price notice mean for BDMD trading?
BDMD shares continue trading uninterrupted on the Nasdaq Capital Market; the notification does not itself result in delisting. Nasdaq requires a minimum bid price of US$1.00 per share and identifies a deficiency when it persists for 30 consecutive business days.
When must Baird Medical regain Nasdaq minimum bid price compliance?
Baird Medical has until May 3, 2027 to regain compliance during its 180-calendar-day compliance period. Its ordinary shares must have a closing bid price of US$1.00 or above for a minimum of ten consecutive business days.
How could Baird Medical qualify for an additional Nasdaq compliance period?
An additional 180-calendar-day grace period requires Baird Medical to meet the continued listing requirement for market value of publicly held shares and all other Nasdaq Capital Market initial listing standards except bid price. It must also provide written notice of its intention to cure the deficiency during that period, together with its proposed compliance plan.